Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
3 Magnificent Stocks to Buy and Hold Forever
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...
STAT2h
The first shot taken at Medicaid, and Optum’s wellness visit ad
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Vertex stock price target raised to $550 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
Newly approved painkiller Journavx is 'potentially groundbreaking'
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
StudyFinds on MSN22h
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
GEN2h
Top 10 Takeover Targets of 2025
Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...